Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, La Jolla, California, USA.
Prog Mol Biol Transl Sci. 2013;115:375-420. doi: 10.1016/B978-0-12-394587-7.00009-9.
Oligomerization of chemokine receptors has been reported to influence many aspects of receptor function through allosteric communication between receptor protomers. Allosteric interactions within chemokine receptor hetero-oligomers have been shown to cause negative cooperativity in the binding of chemokines and to inhibit receptor activation in the case of some receptor pairs. Other receptor pairs can cause enhanced signaling and even activate entirely new, hetero-oligomer-specific signaling complexes and responses downstream of receptor activation. Many mechanisms contribute to these effects including direct allosteric coupling between the receptors, G protein-mediated allostery, G protein stealing, ligand sequestration, and recruitment of new intracellular proteins by exposing unique binding interfaces on the oligomerized receptors. These effects present both challenges as well as exciting opportunities for drug discovery. One of the most difficult challenges will involve determining if and when hetero-oligomers versus homomeric receptors are involved in specific disease states.
趋化因子受体的寡聚化已被报道通过受体原聚体之间的变构通讯影响受体功能的许多方面。趋化因子受体异源寡聚体内部的变构相互作用已被证明导致趋化因子结合的负协同作用,并在某些受体对的情况下抑制受体激活。其他受体对可以引起信号增强,甚至激活全新的、异源寡聚体特异性信号复合物,并在受体激活的下游引起反应。许多机制促成了这些效应,包括受体之间的直接变构偶联、G 蛋白介导的变构作用、G 蛋白窃取、配体隔离以及通过暴露寡聚化受体上独特的结合界面来招募新的细胞内蛋白。这些效应既带来了挑战,也为药物发现带来了令人兴奋的机会。其中最具挑战性的挑战之一将涉及确定在特定疾病状态下,是异源寡聚体还是同源受体参与。